- Home
- CHRS vs IDR Comparison
CHRS vs IDR Comparison
Compare CHRS & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- IDR
- Stock Information
- Founded
- CHRS 2010
- IDR 1996
- Country
- CHRS United States
- IDR United States
- Employees
- CHRS N/A
- IDR N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- IDR Precious Metals
- Sector
- CHRS Health Care
- IDR Basic Materials
- Exchange
- CHRS Nasdaq
- IDR Nasdaq
- Market Cap
- CHRS 159.2M
- IDR 378.0M
- IPO Year
- CHRS 2014
- IDR N/A
- Fundamental
- Price
- CHRS $1.47
- IDR $28.68
- Analyst Decision
- CHRS Strong Buy
- IDR Strong Buy
- Analyst Count
- CHRS 4
- IDR 1
- Target Price
- CHRS $4.51
- IDR $17.50
- AVG Volume (30 Days)
- CHRS 1.2M
- IDR 426.7K
- Earning Date
- CHRS 11-05-2025
- IDR 11-03-2025
- Dividend Yield
- CHRS N/A
- IDR N/A
- EPS Growth
- CHRS N/A
- IDR 57.55
- EPS
- CHRS 1.55
- IDR 0.64
- Revenue
- CHRS $272,209,000.00
- IDR $30,496,328.00
- Revenue This Year
- CHRS N/A
- IDR $21.91
- Revenue Next Year
- CHRS $109.48
- IDR $5.47
- P/E Ratio
- CHRS $0.87
- IDR $45.25
- Revenue Growth
- CHRS 52.33
- IDR 59.64
- 52 Week Low
- CHRS $0.66
- IDR $9.67
- 52 Week High
- CHRS $2.43
- IDR $32.01
- Technical
- Relative Strength Index (RSI)
- CHRS 70.80
- IDR 58.59
- Support Level
- CHRS $1.23
- IDR $27.85
- Resistance Level
- CHRS $1.40
- IDR $32.01
- Average True Range (ATR)
- CHRS 0.09
- IDR 2.00
- MACD
- CHRS 0.00
- IDR -0.25
- Stochastic Oscillator
- CHRS 84.21
- IDR 39.53
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.